Endologix announced on 13 October 2015 that it has received FDA approval for the AFX2 Bifurcated Endograft System for the treatment of abdominal aortic aneurysms. This new device is the latest innovation in the AFX Endovascular AAA family of products. Endologix plans to highlight AFX2 at the 2015 VEITHsymposium taking place 17–21 November in New York, with a commercial launch in the USA expected to begin in the first quarter of 2016.
A retrospective multicentre study has concluded that internal iliac aneurysms that are less than 4cm in diameter have a low risk of rupture, and suggested that the threshold for elective treatment of the condition may be safely increased from 3cm (current practice) to 4cm.
In-stent restenosis patients with severe claudication or critical limb ischaemia should be treated with drug-coated technologies if they present with focal lesions and with a mechanical block such as covered stents if they have diffuse lesions or occlusion, according to Koen Deloose, Dendermonde, Belgium.
Cardinal Health has announced that it has completed the acquisition of Johnson & Johnson’s Cordis business for US $1.944 billion. Planning has been ongoing since the acquisition announcement in early March 2015, and the integration is off to a successful start with management teams in place worldwide. With the Cardinal Health acquisition of Cordis, devices such as the Cordis S.M.A.R.T Vascular Stent Systems are now part of the Cardinal Health portfolio.
NuVascular has partnered with experienced business leaders Paul Sandman, Albert Budney and Mark Radtke to form a new business advisory board. The group brings diverse leadership experience from companies such as Boston Scientific, Niagara Mohawk Holdings and Integrys Energy Group. The new board will work directly with the scientific advisory board and NuVascular founders Eugene Anton and Matthew Phaneuf to commercialise NuVascular’s haemodialysis access products.
Essential Medical has successfully completed additional clinical studies using its Manta 14F large bore vascular closure device, a vascular closure device designed to seal both 14F and 18F large bore femoral punctures.
The CX Imaging Day provided a comprehensive programme of state-of-the-art imaging that is applied to the aorta, carotid, peripheral arteries and veins, including planning and using hybrid theatres, robotics, 3D fusion and guidance, intravascular ultrasound, perfusion angiography, cone beam computed tomography and carbon dioxide angiography.
Michael Dake, Stanford, USA, presented the initial results with the GORE TAG Thoracic Branch Endoprosthesis (TBE), a new device for treatment of the aortic arch at CX yesterday.
There have been vast technological advances that have enabled the final frontier of the aorta, the diseased ascending aorta and arch, to be treated by completely endovascular means. Simultaneously, there have also been advances in open repair. Also, with perioperative stroke remaining a principal risk with TEVAR, the high incidence of cerebral embolisation with the procedure is a problem that needs wider recognition, delegates heard yesterday.
A clinical trial evaluating Eluvia Drug-Eluting Vascular Stent System (Boston Scientific) has met its primary endpoint with more than 94% of the lesions treated remaining open at nine months post implantation. This was accompanied by a target lesion revascularisation rate of less than 4%.
Intact Vascular has announced the publication of the first clinical experience with supporting preclinical data in the Journal of the American College of Cardiology: Cardiovascular Interventions. The article “Early experimental and clinical experience with a focal implant for lower extremity post-angioplasty dissection”, reveals the potential of the Tack endovascular system for the repair of arterial dissections following percutaneous transluminal angioplasty.
Yesterday, for the first time, the Charing Cross International Symposium broadcast peripheral live cases that were directly linked to data presented the previous day on the theme of peripheral arterial controversies. The aim of the course was to provide delegates with opportunities to learn techniques to achieve the best results with the approaches discussed in the data.
The INNOVATION study found that the rate of freedom proximal type I endoleaks and the rate of freedom from reintervention in patients who underwent endovascular aortic aneurysm repair (EVAR) with the Incraft (Cordis) device was, respectively, 100% and 95%, at three years. In this interview, CX Daily News speaks to Giovanni Pratesi (Florence, Italy)—who presented the data at CX yesterday—about Incraft and the three-year results.
According to Janet Powell, Imperial College London, UK, the highest risk factors for rupture of abdominal aortic aneurysms (AAA) are female gender, smoking, increasing age and mean arterial pressure, but there are still few useful indicators of how to manage screen-detected aneurysms to stop them enlarging. Powell put forward this view during yesterday’s Abdominal Aortic Controversies Main Programme which explored epidemiology, indications and medical management of abdominal aortic aneurysms.
Results from the 12-month data of the randomised controlled IMPROVE trial, presented for the first time at CX 2015 (28 April–1May, London, UK), show that an endovascular strategy is cost-effective when compared to open repair in the treatment of ruptured abdominal aortic aneurysms. The one-year data also revealed that the endovascular strategy conferred no survival benefit over open repair, except a trend towards benefitting women. It also showed that the endovascular strategy enabled more patients to be discharged from hospital to home, and significantly faster than with open repair. Patients also have an excellent quality of life with endovascular strategy, if they survive the rupture, delegates heard.
Cookies Sociales
Son esos botones que permiten compartir el contenido del sitio web en sus redes sociales (Facebook, Twitter y Linkedin, previo tu consentimiento y login) a través de sistemas totalmente gestionados por dichas redes sociales, así como los recursos (pej. videos) y material que se encuentra en nuestra web, y que de igual manera se presta y gestiona completamente por un tercero.
Si no acepta estas cookies, no podrá compartir nuestro contenido a través de los botones, y en su caso, no podrás visualizar el contenido de terceros que hayamos incrustado en el sitio.
No las utilizamos